Results 41 to 50 of about 19,637 (185)

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Evaluation of Treatment Response of Calcified Nodules and Nodular Calcified Lesions Using Mean Density on Coronary Computed Tomography Angiography

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Calcified nodules (CN) and nodular calcifications (NC) present significant challenges during percutaneous coronary intervention (PCI) because of their protruding morphology and high rigidity, which often result in inadequate stent expansion and suboptimal procedural outcomes.
Akito Setoguchi, Keita Iyama, Ryosuke Iwasaki, Saburo Kusumoto, Yoshiyuki Doi, Tatsuya Nunohiro, Masayoshi Takeno, Koji Maemura   +7 more
wiley   +1 more source

Multiparticulate Systems of Ezetimibe Micellar System and Atorvastatin Solid Dispersion Efficacy of Low-Dose Ezetimibe/Atorvastatin on High-Fat Diet-Induced Hyperlipidemia and Hepatic Steatosis in Diabetic Rats

Pharmaceutics, 2021
The aim of this study was to develop multiparticulate systems with a combination of ezetimibe micellar systems and atorvastatin solid dispersions using croscarmellose as a hydrophilic vehicle and Kolliphor RH40 as a surfactant.
Carlos Torrado-Salmerón, Víctor Guarnizo-Herrero, Joana Henriques, Raquel Seiça, Cristina M. Sena, Santiago Torrado-Santiago   +5 more
doaj   +1 more source

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

iNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang, Xinyan Li, Honglu Shi, Gaolei Song, Zhifu Xie, Jingya Li   +5 more
wiley   +1 more source

Ezetimibe/simvastatin

, 2009
BACKGROUND: Treatments with ezetimibe/simvastatin (combined or alone) have been indicated as very promising approaches to strongly reduce cholesterol levels in hyperlipidemic patients.
Mach, François, QUERCIOLI, ALESSANDRA MARIA, Quercioli, Alessandra, Montecucco, Fabrizio, Mach F.   +4 more
core   +1 more source

Ezetimibe, Golongan Baru Penurun Kolestrol

, 2021
Abstrak               Penyakit kardiovaskuler tetap meningkat secara dramatis meskipun tersedia banyak obat penurun kolestrol.
Simatupang, Abraham
core   +1 more source

Increased coproporphyrin serum levels in healthy volunteers treated with the cholesterol uptake inhibitor ezetimibe

Clinical and Translational Science
Ezetimibe undergoes glucuronidation that results in the active metabolite ezetimibe phenoxy‐glucuronide (ezetimibe‐glucuronide). This phase‐II metabolite was shown to interact with the clinically relevant hepatic transporter organic anion transporting ...
Jonny Kinzi, Markus Grube, Isabell Seibert, Werner Siegmund, Henriette E. Meyer zu Schwabedissen   +4 more
doaj   +1 more source

Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease

, 2010
Coronary heart disease treatment with HMG-CoA reductase inhibitors has been very successful. There is increasing interest in adding other lipid lowering therapy, primarily as additional therapy onto HMG-CoA reductase therapy.
Robert Guthrie
core   +1 more source

Toward Individualized Atherosclerosis Therapy: Clinical Endotypes, Programmable Therapeutics, and Delivery Constraints

Medicine Bulletin, EarlyView.
ABSTRACT Atherosclerosis remains the dominant substrate of atherosclerotic cardiovascular disease (ASCVD), yet recurrent events persist even when LDL cholesterol is driven to guideline targets, underscoring residual risk as a central limitation of contemporary prevention.
Yundong Peng, Rui Li, Huan Li, Jun Zhou, Xuanshi Liu, Guilherme Valente, Tataiana de Campos Melo, Sifan Chen, Lei Gu   +8 more
wiley   +1 more source

Protosappanin A Alleviates Atherosclerosis by Regulating the MDM2/GPX4 Axis‐Mediated Endothelial Ferroptosis

Phytotherapy Research, EarlyView.
PTA alleviates atherosclerosis by regulating the MDM2/GPX4 axis‐mediated endothelial ferroptosis. ABSTRACT Endothelial ferroptosis is a crucial pathogenic driver of atherosclerosis (AS) progression. Protosappanin A (PTA), a bioactive compound from Caesalpinia sappan L., protects cardiovascular vessels by regulating ferroptosis.
Jiamei Fu, Lin Zhu, Wenwei Yang, Mengnan Li, Zhixin Wu, Shude Sun, Yabin Zhou   +6 more
wiley   +1 more source